Compare TransMedics Group Inc (TMDX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs VNET Group Inc — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while VNET Group Inc trades at $6.53 (market cap $1.92B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VNET | |
|---|---|---|
Market Cap | $3.06B | $1.92B |
Sector | Technology | Technology |
52-Week High | $150.42 | $14.03 |
52-Week Low | $61.99 | $6.06 |
Enterprise Value | $3.46B | $5.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
VNET Group trades at $6.75, up 5.97% today, amid bearish technical signals and mixed fundamentals. The company reported Q2 2026 revenue growth driven by wholesale data center demand but missed earnings expectations with a net loss. Despite a strategic partnership with CATL announced August 2026, negative profit margins and rising leverage remain concerns. Analyst consensus is bullish with 62.5% buy ratings, though technical indicators show selling pressure.
Outlook: Growth potential exists from AI infrastructure demand and new capacity, but high debt and consistent losses pose significant risks. Investors should weigh strong institutional support against fundamental weaknesses and ongoing class action litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
